

Bimatoprost (Lumigan®)
Allergan Ltd

(No. 07/02)

Summary of Recommendation

9 August 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for general use within the NHS in Scotland.

REASONS FOR ADVICE

Recommended for general use within the NHS in Scotland as adjunctive therapy to beta-blockers or as monotherapy in patients insufficiently responsive to, intolerant of or contra-indicated to first-line therapy. It should be used under the direction of an ophthalmologist.

Professor David H Lawson
Chairman